Skip to content

Interest Paid at other companies

Royalty Pharma logo
Royalty PharmaRPRX
$173.53M+25.0%
Revvity logo
RevvityRVTY
$21.55M-5.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$20.32M-12.7%
Roivant Sciences logo
Roivant SciencesROIV
$0-100%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$90K-2.2%
ALN
Alnylam PharmaceuticalsALNY
$64.2M-6.9%

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.6B+96.7%

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InterestPaidNet.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's interest paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's interest paid?
Ligand Pharmaceuticals (LGND) reported interest paid of $97K in Q1 2026.
How has Ligand Pharmaceuticals's interest paid changed year-over-year?
Ligand Pharmaceuticals's interest paid decreased by 0.0% year-over-year, from $97K to $97K.
What is the long-term trend for Ligand Pharmaceuticals's interest paid?
Over 3 years (2021 to 2025), Ligand Pharmaceuticals's interest paid has grown at a -52.7% compound annual growth rate (CAGR), from $3.03M to $321K.
What does interest paid mean?
Supplemental disclosure of total cash interest paid on all debt and lease obligations during the period.